Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -84.14 Million USD | 16.15% |
| 2023 | -69.13 Million USD | 14.6% |
| 2022 | -80.95 Million USD | 27.63% |
| 2021 | -111.86 Million USD | -41.47% |
| 2020 | -79.07 Million USD | 5.08% |
| 2019 | -83.3 Million USD | -7.71% |
| 2018 | -77.33 Million USD | 16.85% |
| 2017 | -93.01 Million USD | -207.32% |
| 2016 | -30.26 Million USD | 74.31% |
| 2015 | -117.82 Million USD | -72.94% |
| 2014 | -68.12 Million USD | -13.4% |
| 2013 | -60.07 Million USD | -23.31% |
| 2012 | -48.72 Million USD | -151.96% |
| 2011 | 93.76 Million USD | 1002.7% |
| 2010 | -10.38 Million USD | -10.16% |
| 2009 | -9.42 Million USD | -18.76% |
| 2008 | -7.93 Million USD | -13.2% |
| 2007 | -7.01 Million USD | -11.61% |
| 2006 | -6.28 Million USD | -536.98% |
| 2005 | -986.54 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -22 Million USD | -9.67% |
| 2024 Q4 | -22 Million USD | 0.0% |
| 2024 FY | -59.8 Million USD | 13.49% |
| 2024 Q1 | -13.29 Million USD | 29.72% |
| 2024 Q2 | -20.06 Million USD | -50.97% |
| 2023 Q3 | -14.46 Million USD | 31.5% |
| 2023 Q1 | -16 Million USD | 18.9% |
| 2023 Q4 | -18.91 Million USD | -30.76% |
| 2023 FY | -69.13 Million USD | 14.6% |
| 2023 Q2 | -21.11 Million USD | -31.92% |
| 2022 Q3 | -19.34 Million USD | 17.83% |
| 2022 Q4 | -19.73 Million USD | -2.05% |
| 2022 FY | -80.95 Million USD | 27.63% |
| 2022 Q1 | -19.32 Million USD | -0.17% |
| 2022 Q2 | -23.53 Million USD | -21.78% |
| 2021 Q2 | -27.36 Million USD | 29.05% |
| 2021 Q1 | -38.56 Million USD | -20.56% |
| 2021 Q4 | -19.29 Million USD | 25.52% |
| 2021 FY | -111.86 Million USD | -41.47% |
| 2021 Q3 | -25.9 Million USD | 5.32% |
| 2020 Q4 | -31.98 Million USD | -106.11% |
| 2020 FY | -79.07 Million USD | 5.08% |
| 2020 Q3 | -15.52 Million USD | 34.56% |
| 2020 Q2 | -23.71 Million USD | -507.64% |
| 2020 Q1 | -3.9 Million USD | 78.41% |
| 2019 Q3 | -22.21 Million USD | 8.2% |
| 2019 Q2 | -24.19 Million USD | -44.18% |
| 2019 Q1 | -16.78 Million USD | 29.17% |
| 2019 FY | -83.3 Million USD | -7.71% |
| 2019 Q4 | -18.07 Million USD | 18.61% |
| 2018 Q1 | -20.08 Million USD | 13.99% |
| 2018 FY | -77.33 Million USD | 16.85% |
| 2018 Q3 | -24.43 Million USD | -163.66% |
| 2018 Q2 | -9.26 Million USD | 53.85% |
| 2018 Q4 | -23.69 Million USD | 3.04% |
| 2017 Q3 | -21.99 Million USD | 3.75% |
| 2017 Q4 | -23.35 Million USD | -6.17% |
| 2017 FY | -93.01 Million USD | -207.32% |
| 2017 Q2 | -22.85 Million USD | -4.39% |
| 2017 Q1 | -21.89 Million USD | -160.51% |
| 2016 Q2 | -21.79 Million USD | -50.67% |
| 2016 Q3 | -20.46 Million USD | 6.12% |
| 2016 FY | -30.26 Million USD | 74.31% |
| 2016 Q1 | -14.46 Million USD | 70.37% |
| 2016 Q4 | 36.17 Million USD | 276.81% |
| 2015 Q3 | -17.25 Million USD | 41.28% |
| 2015 Q4 | -48.81 Million USD | -182.86% |
| 2015 Q2 | -29.39 Million USD | -77.14% |
| 2015 Q1 | -16.59 Million USD | 10.7% |
| 2015 FY | -117.82 Million USD | -72.94% |
| 2014 Q2 | -18.51 Million USD | -76.69% |
| 2014 Q4 | -18.58 Million USD | 1.35% |
| 2014 FY | -68.12 Million USD | -13.4% |
| 2014 Q1 | -10.47 Million USD | 27.11% |
| 2014 Q3 | -18.83 Million USD | -1.74% |
| 2013 Q4 | -14.37 Million USD | 12.05% |
| 2013 FY | -60.07 Million USD | -23.31% |
| 2013 Q3 | -16.34 Million USD | 0.0% |
| 2012 FY | -48.72 Million USD | -151.96% |
| 2011 FY | 93.76 Million USD | 1002.7% |
| 2010 FY | -10.38 Million USD | -10.16% |
| 2009 FY | -9.42 Million USD | -18.76% |
| 2008 FY | -7.93 Million USD | -13.2% |
| 2007 FY | -7.01 Million USD | -11.61% |
| 2006 FY | -6.28 Million USD | -536.98% |
| 2005 FY | -986.54 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -6201.112% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1568.1% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -371.491% |
| Nascent Biotech, Inc. | -2.22 Million USD | -3673.613% |
| Rebus Holdings, Inc. | -664 Thousand USD | -12572.741% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 202.804% |
| Qrons Inc. | -643.67 Thousand USD | -12972.861% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -21499.969% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -51.594% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -20153.009% |
| Skye Bioscience, Inc. | -13.67 Million USD | -515.479% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -17.219% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1812.111% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -32050.799% |
| SQZ Biotechnologies Company | -75.82 Million USD | -10.975% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -2852.001% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -5378.146% |
| Marizyme, Inc. | -34.08 Million USD | -146.863% |
| Genus plc | 6.4 Million USD | 1414.797% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 963.714% |
| Pharming Group N.V. | -4.87 Million USD | -1624.485% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -4135.987% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -8934.658% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -907.749% |
| ContraFect Corporation | -56.88 Million USD | -47.914% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -1747.466% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -5901.964% |
| IMV Inc. | -38.67 Million USD | -117.594% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -2958.958% |
| MultiCell Technologies, Inc. | -722.81 USD | -11641548.566% |
| ONE Bio Corp. | 13.68 Million USD | 715.04% |
| Accustem Sciences Inc. | -3.74 Million USD | -2146.065% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -42.646% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -17319.503% |
| Q BioMed Inc. | -3.44 Million USD | -2342.147% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 2477.034% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -3102.523% |
| Biomind Labs Inc. | -1 Million USD | -8234.662% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -53.071% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -2800.371% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1165.746% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -4413.428% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -280839.503% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -430.236% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -4254.06% |
| GB Sciences, Inc. | -1.42 Million USD | -5823.722% |
| Alpha Cognition Inc. | -9.7 Million USD | -766.994% |
| HST Global, Inc. | -140.9 Thousand USD | -59618.112% |
| CSL Limited | 3.7 Billion USD | 102.273% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -7380.358% |
| Halberd Corporation | -75.05 Thousand USD | -112021.252% |
| Enzolytics Inc. | -2.14 Million USD | -3816.0% |
| Agentix Corp. | -1.37 Million USD | -6034.254% |
| Resverlogix Corp. | -12.74 Million USD | -560.028% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -2555.926% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 80.203% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -7960.057% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -2782.295% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -5227.935% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -2371.293% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1357.261% |
| Zenith Capital Corp. | -8.94 Million USD | -840.926% |
| Genscript Biotech Corporation | -415.79 Million USD | 79.762% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -482920.493% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -3327.134% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -48962.577% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4097.367% |
| Kadimastem Ltd | -3.04 Million USD | -2667.766% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -8451.064% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -6599.602% |
| BioStem Technologies, Inc. | -7.77 Million USD | -981.724% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -46265.815% |
| LadRx Corporation | -3.82 Million USD | -2100.712% |
| Cell Source, Inc. | -4.32 Million USD | -1845.44% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -12149.363% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -12149.363% |
| NovAccess Global Inc. | -2.46 Million USD | -3311.236% |
| Affymax, Inc. | -15.04 Million USD | -459.265% |
| Itoco Inc. | -919.14 Thousand USD | -9054.971% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1885.342% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -7419.839% |
| Mobile Lads Corp. | -554.55 Thousand USD | -15073.925% |
| CytoDyn Inc. | -18.05 Million USD | -365.982% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -334214.66% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -38135.08% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -14800.58% |
| SYBLEU INC | -149.18 Thousand USD | -56306.355% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -4532.829% |
| International Stem Cell Corporation | -663 Thousand USD | -12591.855% |
| Bioxytran, Inc. | -3.82 Million USD | -2102.716% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -159753.723% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -413602.065% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -132.027% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -5100.68% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -11335.58% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -2604.822% |
| Neutra Corp. | -229.48 Thousand USD | -36567.596% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -379.771% |
| PureTech Health plc | -146.19 Million USD | 42.444% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -291.543% |
| IXICO plc | -1.43 Million USD | -5755.741% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -786.598% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 30.917% |
| CSL Limited | 3.81 Billion USD | 102.207% |
| Cellectis S.A. | -108.85 Million USD | 22.7% |